IDEXX Laboratories, Inc. $IDXX Stock Holdings Increased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 88.2% in the first quarter, HoldingsChannel reports. The fund owned 12,011 shares of the company’s stock after buying an additional 5,628 shares during the period. OMERS ADMINISTRATION Corp’s holdings in IDEXX Laboratories were worth $6,749,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at $26,000. Virtus Advisers LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $26,000. Mowery & Schoenfeld Wealth Management LLC grew its position in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares in the last quarter. Wormser Freres Gestion increased its stake in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. Finally, WealthCollab LLC acquired a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on IDXX shares. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group lowered their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $544.32 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm’s 50 day moving average is $556.27 and its 200-day moving average is $594.80. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The stock has a market capitalization of $42.94 billion, a P/E ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.